Abstract
The British Association of Dermatologists Biologics and Immunomodulator Register (BADBIR) prospectively records real-world outcomes for patients with psoriasis in the UK and Republic of Ireland receiving biologic and non-biologic immunomodulators. This study described baseline demographics, drug survival and effectiveness in biologic-naïve versus biologic-experienced patients with psoriasis initiating the interleukin-17A antagonist ixekizumab.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
